Cybin Inc. (CYBN)
AMEX: CYBN
· Real-Time Price · USD
6.11
-0.09 (-1.45%)
At close: Oct 16, 2025, 3:59 PM
6.05
-0.98%
After-hours: Oct 16, 2025, 07:59 PM EDT
-1.45% (1D)
| Bid | 6.02 |
| Market Cap | 144.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -122.93M |
| EPS (ttm) | -4.47 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | -1.22 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.3 |
| Volume | 519,056 |
| Avg. Volume (20D) | 573,735 |
| Open | 6.25 |
| Previous Close | 6.20 |
| Day's Range | 6.04 - 6.28 |
| 52-Week Range | 4.81 - 13.88 |
| Beta | 1.06 |
| Ex-Dividend Date | n/a |
About CYBN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYBN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYBN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+1.4%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
3 months ago
+12.5%
Cybin shares are trading higher after the company announced it has received approval to commence its EMBRACE study of CYB003.
3 weeks ago · businesswire.com
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical MilestonesTORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
2 months ago · businesswire.com
Cybin to Participate in the Canaccord Genuity 45th Annual Growth ConferenceTORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcar...
